Abstract
Objective In the antenatal late preterm steroids (ALPS) trial betamethasone significantly decreased short-term neonatal respiratory morbidity but increased the risk of neonatal hypoglycemia, diagnosed only categorically (72 hours was rare and similar in both groups, nine (2.4%, betamethasone) and four (1.9%, placebo, p = 0.18). Conclusion In this cohort, hypoglycemia was transient and most received no treatment, with a quicker resolution in the betamethasone group. Prolonged hypoglycemia was uncommon irrespective of steroid exposure. Key Points * Additional members of this network are listed in [ Supplementary Material ] (available in the online version). Received: 08 October 2020 Accepted: 16 March 2021 Article published online: 27 May 2021 © 2021. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
Funding Information
  • NHLBI (HL098554)
  • NHLBI (HL098354)
  • NICHD (HD21410)
  • NICHD (HD27915)
  • NICHD (HD27917)
  • NICHD (HD27869)
  • NICHD (HD34116)
  • NICHD (HD34208)
  • NICHD (HD40485)
  • NICHD (HD40500)
  • NICHD (HD40512)
  • NICHD (HD40544)
  • NICHD (HD40545)
  • NICHD (HD40560)
  • NICHD (HD53097)
  • NICHD (HD53118)
  • NICHD (HD68268)
  • NICHD (HD68258)
  • NICHD (HD68282)
  • NICHD (HD36801)
  • National Center for Advancing Translational Sciences, National Institutes of Health (UL1 TR000040)

This publication has 20 references indexed in Scilit: